大洋生物(003017.SZ)業績快報:2021年度淨利降23.49%至7008.44萬元
格隆匯3月22日丨大洋生物(003017.SZ)披露2021年度業績快報,報吿期內,公司實現營業總收入7.83億元,同比增長15.46%;營業利潤7932.55萬元,利潤總額7613.84萬元,歸屬於上市公司股東的淨利潤7008.44萬元,分別同比下降22.01%、24.06%和23.49%。
報吿期內,化工產業鏈整體出現價格大幅波動。公司在主要原材料氯化鉀、煙煤採購價格達近10年來新高的大背景下,通過強化市場信息分析研判,充足備貨量,來有效滯緩產品成本的快速增長;同時相應調整銷售定價,以維護經營業績的總體平穩。
報吿期末,公司總資產13.74億元、歸屬於上市公司股東的所有者權益9.91億元,分別同比上升11.85%和3.41%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.